CM313 injection

BIOLOGICAL7 trials

Conditions

HealthyImmune ThrombocytopeniaMultiple MyelomaPemphigusPrimary Immune ThrombocytopeniaSystemic Lupus ErythematosusTreatment

Phase 1

A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma

Not yet recruitingNCT06126237

Keymed Biosciences Co.LtdMultiple Myeloma

Start: 2024-02-28End: 2026-02-28Target: 120Updated: 2023-11-13

Study of CM313 in Healthy Subjects

RecruitingNCT06285227

Keymed Biosciences Co.LtdHealthy

Start: 2024-03-12End: 2025-04-30Target: 51Updated: 2024-10-16

Phase 2

A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia

CompletedNCT05694767

Institute of Hematology & Blood Diseases Hospital, ChinaImmune Thrombocytopenia, Treatment

Start: 2023-01-22End: 2023-12-30Updated: 2025-02-24

A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia

Active, not recruitingNCT06199089

Institute of Hematology & Blood Diseases Hospital, ChinaImmune Thrombocytopenia, Treatment

Start: 2024-01-16End: 2024-12-31Updated: 2024-12-30

Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)

Active, not recruitingNCT06594146

Keymed Biosciences Co.LtdPrimary Immune Thrombocytopenia

Start: 2024-11-11End: 2025-12-30Updated: 2025-04-23

Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)

Not yet recruitingNCT06791772

Keymed Biosciences Co.LtdSystemic Lupus Erythematosus

Start: 2025-02-28End: 2027-02-28Target: 150Updated: 2025-01-24

Unknown Phase

A Single-center Study of CM313 in Patients With Pemphigus

Not yet recruitingNCT06904040

Sichuan Provincial People's HospitalPemphigus

Start: 2025-04-01End: 2028-04-01Target: 20Updated: 2025-04-01

Related Papers

Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.

2025-10-21

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of <scp>CM313</scp> in Healthy Participants: An Open‐Label/Double‐Blind, Randomized, Placebo‐Controlled Phase 1 Trial

Clinical and Translational Science2025-09-01

A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia

New England Journal of Medicine2024-06-1935 citations

CM313, a Novel Anti-CD38 Antibody, As a Potential Treatment for Primary Immune Thrombocytopenia: A Phase II Trial

Blood2023-11-022 citations